For Pfizer's Prevnar 13 pneumococcal vaccine, should we prioritize expanding age group indications or focusing on new serotype coverage?

Introduction

The trade-off we're examining today is whether Pfizer should prioritize expanding age group indications or focus on new serotype coverage for their Prevnar 13 pneumococcal vaccine. This decision involves balancing market expansion with product improvement, both of which could significantly impact public health and Pfizer's market position. I'll analyze this trade-off by examining the product context, potential impacts, key metrics, and experimental approaches to inform a strategic recommendation.

Step 1

Clarifying Questions (3 minutes)

• Based on recent market trends, I'm thinking Prevnar 13 might be facing increased competition. Could you provide an overview of the current competitive landscape for pneumococcal vaccines?

Why it matters: Helps assess the urgency of product improvements vs. market expansion Expected answer: Several new entrants with broader serotype coverage Impact on approach: Would lean towards focusing on new serotype coverage if competition is intensifying

• Considering Pfizer's global presence, I'm curious about the geographic distribution of Prevnar 13 sales. Could you share insights on which markets are currently the strongest performers and where we see the most growth potential?

Why it matters: Informs whether age group expansion or serotype coverage would be more impactful in key markets Expected answer: Strong in developed markets, growth potential in emerging economies Impact on approach: Might prioritize age group expansion if there's significant untapped potential in current markets

• Looking at our manufacturing capabilities, I'm wondering about our capacity to develop and produce a new formulation with expanded serotype coverage. What's our current production flexibility and timeline for potential new formulations?

Why it matters: Assesses feasibility and time-to-market for new serotype coverage Expected answer: 2-3 years for new formulation development and scaling Impact on approach: Longer timeline might favor age group expansion as a quicker win

• Considering the regulatory landscape, I'm thinking about the approval processes for age group expansion versus new serotype coverage. Could you outline the key differences in regulatory requirements and timelines for these two paths?

Why it matters: Impacts speed to market and resource allocation Expected answer: Age group expansion typically faster, new serotype coverage requires more extensive trials Impact on approach: Might lean towards age group expansion if regulatory hurdles are significantly lower

• Given the public health implications, I'm curious about any ongoing discussions with health organizations or government bodies regarding pneumococcal vaccination strategies. Are there any emerging priorities or recommendations that could influence our decision?

Why it matters: Aligns product strategy with broader public health goals Expected answer: Increasing focus on adult vaccination and broader serotype coverage Impact on approach: Would consider balancing both options if there's strong support for both directions